Comunicados de prensa de Eli Lilly

INDIANAPOLIS, Oct. 15, 2026 /PRNewswire/ -- Eli Lilly and Company (NYSE: LLY) will announce its third-quarter 2026 financial results on October 29, 2026. Lilly will also conduct a conference call that…

Exploratory data presented at Fall Clinical 2026 showed broader biomarker changes with Taltz and Zepbound vs. Taltz alone as early as Week 12 in first-of-its-kind TOGETHER-PsO study INDIANAPOLIS, Oct.…

RENO, Nev., Oct. 06, 2026 (GLOBE NEWSWIRE) -- Wall Street Investor News Commentary - The global advanced wound care market is valued at $13.37 billion in 2025 and is projected to reach $19.32 billion…

INDIANAPOLIS, Oct. 2, 2026 /PRNewswire/ -- Eli Lilly and Company (NYSE: LLY) announced today that the U.S. Food and Drug Administration (FDA) has approved an additional indication for Jaypirca (pirtob…

Participants taking EloraTZP lost up to an average of 54.1 lbs (23.3%) compared to 34.4 lbs (14.8%) with tirzepatide 15 mg Participants taking EloraTZP lowered their A1C by up to an average of 2.9% co…

EBGLYSS monotherapy met its primary endpoint with more than half of patients achieving clear or almost clear skin on their hands and feet (HF-IGA 0/1) by Week 16, with significant skin clearance as ea…

In TRIUMPH-2, participants with obesity and type 2 diabetes taking retatrutide 12 mg lost an average of 49.6 lbs (20.8%) over 80 weeks, with more than half no longer meeting the BMI criteria for obesi…

In this new analysis, Zepbound 15 mg showed 4.5% greater weight loss than Wegovy HD in adults with obesity Participants receiving Zepbound 15 mg had more than three times the odds of achieving at leas…

Foundayo 17.2 mg was associated with 1.5% greater weight loss and 0.3% greater A1C reduction than oral semaglutide 25 mg at 52 weeks These additional analyses build on findings of the ACHIEVE-3 head-t…

Through this commitment, Lilly aims to expand access to its innovative diabetes and obesity medicines to as many people in resource-limited settings, including low- and middle-income countries (LMICs)…

FDA approval supported by data from BRAVE-AA-PEDS, the first and largest Phase 3 study specifically designed to evaluate pediatric patients with severe alopecia areata (AA) Treatment with Olumiant res…

Onswik is designed to reduce injections by over 300 per year versus once-daily basal insulin1,2 With Onswik, Lilly's type 2 diabetes portfolio expands to include a once-weekly basal insulin, alongside…

New facility will manufacture active pharmaceutical ingredients for medicines like Foundayo (orforglipron), strengthening domestic supply chain Site will employ more than 600 people in high-wage jobs…

Inluriyo plus Verzenio delivers proven clinical benefit after the evidence-based practice of maximizing initial treatment with an aromatase inhibitor, with or without a CDK4/6 inhibitor In the Phase 3…

Pivotal results from TRIUMPH-2 showed retatrutide, an investigational triple hormone receptor agonist, delivered substantial weight loss and A1C improvements in obesity and type 2 diabetes Findings fr…

INDIANAPOLIS, Sept. 11, 2026 /PRNewswire/ -- Eli Lilly and Company (NYSE: LLY) today announced the successful completion of its acquisition of AtaiBeckley Inc. AtaiBeckley is a clinical-stage biopharm…

INDIANAPOLIS, Sept. 1, 2026 /PRNewswire/ -- Eli Lilly and Company (NYSE: LLY) will participate in the Morgan Stanley 24 th Annual Global Healthcare Conference on September 14, 2026. Ilya Yuffa, execut…